Longitudinal association between CSF markers of Alzheimer Disease and inflammation in preclinical Alzheimer Disease
- Published on 01/08/2025
- Reading time: 4 min.
Isabel MacKenzie Sarty 1,2, Cynthia Picard 3,4, Anne Labonte 5,6, John C.S. Breitner 6,7,8, Judes Poirier 3,6,7,9
1 Integrated Program in Neuroscience, Faculty of Medicine and Health Science, McGill University, Montreal, QC Canada
2 Department of Psychiatry, McGill University, Montreal, QC Canada
3 Douglas Mental Health Research Centre, Montreal, QC Canada
4 Centre for Studies on Prevention of Alzheimer’s Disease (StoP‐AD Centre), Montréal, QC Canada
5 Centre for Studies on Prevention of Alzheimer’s disease (StoP‐AD Centre), Douglas Mental Health Institute, Montreal, QC Canada
6 Centre for Studies on Prevention of Alzheimer’s disease (StoP‐AD Centre), Montreal, QC Canada
7 Department of Psychiatry, McGill University, Montréal, QC Canada
8 Douglas Mental Health University Institute, Montréal, QC Canada
9 Department of Medicine, McGill University, Montréal, QC Canada
Abstract
Background Inflammation is central to Alzheimer Disease (AD), as astrocyte reactivity accompanies the appearance of Aβ and phosphorylated tau (Bellaver et al., 2023). As expected, therefore, AD patients have elevated levels of CSF inflammatory cytokines (Onyango et al., 2021). To understand the importance of these phenomena, exploration of individual inflammatory markers before and at the time of dementia onset is needed. To uncover key CK/Rs involved in the early...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Neurology
Receive our newsletter to stay up to date with the latest news in Neurology
